Want to see AU:EMV full AI Analyst Report?
Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$1.50
▼(-15.25% Downside)
Action:Reiterated
Date:10/29/25
The overall stock score of 44 reflects significant financial challenges, including declining revenues and persistent losses. The technical analysis indicates weak momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively suggest a cautious outlook for the stock.
Positive Factors
Portable brain‑imaging platform
EMvision's core technology targets point-of-care brain imaging for stroke and TBI, a durable clinical need in emergency and pre-hospital care. If commercialized, the platform addresses structural demand for faster diagnosis outside radiology suites, supporting long-term adoption in acute care workflows.
Negative Factors
Significant revenue decline
A -37% revenue contraction is a durable red flag for commercialization and market traction. Sustained declines erode bargaining power, slow scale benefits, and increase the likelihood of further cash burn or dilutive financings. Recovering from this level of contraction will take multiple quarters of consistent commercial execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Portable brain‑imaging platform
EMvision's core technology targets point-of-care brain imaging for stroke and TBI, a durable clinical need in emergency and pre-hospital care. If commercialized, the platform addresses structural demand for faster diagnosis outside radiology suites, supporting long-term adoption in acute care workflows.
Read all positive factors
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$150.59M
Dividend YieldN/A
Average Volume (3M)120.98K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue GrowthN/A
EPS Growth-62.15%
CountryAU
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.12
Shares Outstanding92,955,560
10 Day Avg. Volume127,185
30 Day Avg. Volume120,982
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)16.01
Price to Sales (P/S)29.42
P/FCF Ratio-18.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.11
Revenue Forecast (FY)AU$5.00M
EMvision Medical Devices Ltd. Business Overview & Revenue Model
Company Description
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile bra...
How the Company Makes Money
null...
EMvision Medical Devices Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56M | 5.05M | 11.22M | 6.97M | 4.36M | 1.70M |
| Gross Profit | 1.35M | 5.05M | 11.22M | 6.63M | 4.12M | 1.58M |
| EBITDA | -12.99M | -8.71M | -8.35M | -5.99M | -7.84M | -9.56M |
| Net Income | -10.20M | -9.81M | -2.73M | -3.87M | -6.11M | -8.40M |
Balance Sheet | ||||||
| Total Assets | 24.94M | 15.57M | 23.97M | 11.52M | 8.51M | 10.77M |
| Cash, Cash Equivalents and Short-Term Investments | 17.56M | 10.53M | 18.67M | 9.97M | 6.80M | 9.69M |
| Total Debt | 4.02M | 3.53M | 2.90M | 3.04M | 737.86K | 213.17K |
| Total Liabilities | 5.20M | 6.29M | 5.46M | 6.40M | 1.43M | 720.01K |
| Stockholders Equity | 19.74M | 9.28M | 18.52M | 5.12M | 7.08M | 10.05M |
Cash Flow | ||||||
| Free Cash Flow | -9.02M | -7.89M | -6.29M | 646.86K | -3.97M | -4.62M |
| Operating Cash Flow | -8.94M | -7.84M | -5.99M | 834.15K | -3.78M | -4.49M |
| Investing Cash Flow | -78.32K | -50.37K | -302.41K | -187.29K | -191.12K | -127.25K |
| Financing Cash Flow | 12.96M | -258.34K | 15.00M | 2.52M | 1.08M | 8.90M |
EMvision Medical Devices Ltd. Technical Analysis
Neutral
1.77
Price Trends
1.63
Negative
1.65
Negative
1.74
Negative
Market Momentum
<0.01
Negative
53.22
Neutral
77.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMV, the sentiment is Neutral. The current price of 1.77 is above the 20-day moving average (MA) of 1.55, above the 50-day MA of 1.63, and above the 200-day MA of 1.74, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 77.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:EMV.
EMvision Medical Devices Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$21.08M | -6.96 | -87.19% | ― | -99.13% | 69.17% | |
49 Neutral | AU$30.49M | -3.35 | -98.14% | ― | 14.88% | 35.94% | |
45 Neutral | AU$1.92B | -9.90 | -890.76% | ― | -0.80% | -249.48% | |
44 Neutral | AU$150.59M | -13.79 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$43.95M | 550.00 | 0.48% | ― | 24.45% | ― | |
42 Neutral | AU$75.44M | -3.84 | -54.48% | ― | 17.24% | -20.00% |
* Healthcare Sector Average
AU:EMV
EMvision Medical Devices Ltd.
1.62
-0.12
-6.90%
AU:CMP
Compumedics Limited
0.22
-0.06
-22.81%
AU:NTI
Neurotech International
0.02
>-0.01
-23.81%
AU:CYC
Cyclopharm Limited
0.60
-0.48
-44.44%
AU:CBL
Control Bionics Ltd.
0.07
0.03
60.47%
AU:4DX
4DMedical Ltd
3.20
2.94
1130.77%
EMvision Medical Devices Ltd. Corporate Events
EMVision Advances Pivotal Brain Scanner Trial and Strengthens Funding Base
Jul 14, 2026
EMVision reported strong progress in its pivotal validation trial for the emu™ point-of-care brain scanner, surpassing key enrolment milestones across U.S. and Australian hospitals and integrating smoothly into code stroke workflows. The tri...
EMVision Secures Nature-Portfolio Validation for AI Stroke Scanner
Jul 14, 2026
EMVision’s EMView study, using its emu™ RF brain scanner and proprietary deep-learning models, has been published in npj Digital Medicine, offering peer-reviewed validation of the platform and its AI methods. The research highlights st...
EMVision aeromedical trial de-risks rural stroke scanner deployment
May 26, 2026
EMVision Medical Devices has completed a feasibility and usability study of its First Responder Brain Scanner in an aeromedical retrieval setting with the Royal Flying Doctor Service, the Australian Stroke Alliance and the South Australian Ambulan...
EMVision issues new shares under employee incentive plan with cleansing notice
May 11, 2026
EMVision Medical Devices has issued 16,957 fully paid ordinary shares following the exercise of an equal number of unlisted performance rights under its Employee Incentive Plan. The company confirmed that these shares qualify for on-sale without a...
EMvision Lists New Tranche of Ordinary Shares on ASX
May 11, 2026
EMvision Medical Devices Ltd., an ASX-listed medtech company, has issued a small tranche of 16,957 fully paid ordinary shares. The new securities have been approved for quotation on the ASX, modestly increasing the company’s listed share cap...
EMVision expands pivotal emu brain scanner trial to include acute ischaemia detection
May 10, 2026
EMVision is expanding the scope of its pivotal validation trial for the emu brain scanner to include acute ischaemia detection alongside haemorrhage detection, leveraging progress from a parallel Continuous Innovation study. This simultaneous vali...
EMvision Director Increases Stake with On-Market Share Purchase
Apr 23, 2026
EMvision Medical Devices has reported a change in director Carmel Monaghan’s holdings, following an on-market purchase of additional equity in the company. Monaghan acquired 10,000 ordinary shares on 22 April 2026 for a total consideration o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.